1. Home
  2. AVXL vs SOPH Comparison

AVXL vs SOPH Comparison

Compare AVXL & SOPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Anavex Life Sciences Corp.

AVXL

Anavex Life Sciences Corp.

N/A

Current Price

$4.78

Market Cap

388.7M

Sector

Health Care

ML Signal

N/A

SOPH

SOPHiA GENETICS SA

N/A

Current Price

$4.49

Market Cap

367.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AVXL
SOPH
Founded
2004
2011
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
388.7M
367.7M
IPO Year
2013
2021

Fundamental Metrics

Financial Performance
Metric
AVXL
SOPH
Price
$4.78
$4.49
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
2
Target Price
$22.00
$7.00
AVG Volume (30 Days)
1.0M
112.4K
Earning Date
04-27-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$18.48
Revenue Next Year
N/A
$16.25
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.86
$2.58
52 Week High
$13.99
$5.70

Technical Indicators

Market Signals
Indicator
AVXL
SOPH
Relative Strength Index (RSI) 59.16 42.97
Support Level $3.60 $3.79
Resistance Level $4.88 $4.86
Average True Range (ATR) 0.26 0.30
MACD 0.07 -0.02
Stochastic Oscillator 65.87 45.59

Price Performance

Historical Comparison
AVXL
SOPH

About AVXL Anavex Life Sciences Corp.

Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.

About SOPH SOPHiA GENETICS SA

Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.

Share on Social Networks: